Show simple item record

dc.contributor.authorKattepur, AK
dc.contributor.authorGulia, A
dc.contributor.authorJones, RL
dc.contributor.authorRastogi, S
dc.date.accessioned2021-05-25T13:22:15Z
dc.date.available2021-05-25T13:22:15Z
dc.identifier.citationFuture oncology (London, England), 2021, 17 (7), pp. 825 - 835
dc.identifier.issn1479-6694
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4580
dc.identifier.eissn1744-8301
dc.identifier.eissn1744-8301en_US
dc.identifier.doi10.2217/fon-2020-0802
dc.identifier.doi10.2217/fon-2020-0802en_US
dc.description.abstractExtraskeletal osteosarcoma is a very infrequently diagnosed soft-tissue sarcoma subtype which has identical histological features to bone osteosarcoma. However, its demographics, presentation, radiology and treatment strategy differ from those of osteosarcoma. Its diagnosis can be at times challenging due to radiological and pathological mimics which have more common incidence. A multimodality approach is essential for optimizing the outcomes in extraskeletal osteosarcoma. Although there are certain caveats on inclusion of adjuvant therapies (radiotherapy and chemotherapy), in all cases surgical resection with wide local margins is considered the gold standard for adequate local control. The outcome in advanced disease remains dismal and there is a huge unmet need for prospective studies addressing the optimal treatment strategy. In this article, we review the evidence available for the management of extraskeletal osteosarcoma.
dc.formatPrint-Electronic
dc.format.extent825 - 835
dc.languageeng
dc.language.isoeng
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserved
dc.titleExtraskeletal osteosarcomas: current update.
dc.typeJournal Article
dcterms.dateAccepted2020-11-18
rioxxterms.versionVoR
rioxxterms.versionofrecord10.2217/fon-2020-0802
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfFuture oncology (London, England)
pubs.issue7
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume17en_US
pubs.embargo.termsNot known
icr.researchteamSarcoma Clinical Trials (R Jones)
icr.researchteamSarcoma Clinical Trials (R Jones)en_US
dc.contributor.icrauthorJones, Robinen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record